FSD Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUGE research report →
About the company
FSD Pharma Inc. is a biopharmaceutical research and development company, operating through its various subsidiaries. The firm's leading drug candidate, FSD-201, is currently undergoing Phase II clinical trials for the treatment of COVID-19 disease.
- CEO
- Zeeshan Saeed
- IPO
- 2018
- Employees
- 17
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $66.67K
- P/E
- -0.15
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- 0.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -108.36%
- ROIC
- -192.35%
- Revenue
- $0 · 0.00%
- Net Income
- $-18,564,915 · 20.40%
- EPS
- $-0.47 · 21.67%
- Op Income
- $-19,929,008
- FCF YoY
- 61.58%
- 52W High
- $109.19
- 52W Low
- $0.09
- 50D MA
- $8.13
- 200D MA
- $36.69
- Beta
- 0.85
- Avg Volume
- 196.16K
Get TickerSpark's AI analysis on HUGE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HUGE coverage
Recent articles, reports, and earnings notes.
No research on HUGE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HUGE report →Similar companies
Peers in the same neighborhood.